Beat on adj. EBIT but lower OCF Adj. EBIT up 8.9-9.
Adj. EBIT +85% vs ABGSCe Soft cash flow generation Estimates likely up 10% on adj.
Q4'24 results due 11 February '25e-'26e adj. EBIT revised by 0.
- Adj. EBIT better but OCF down in Q3 - Transition in progress - Adj.
- Weak on sales but higher gross margin - More restrucrings to come - Estimates likely up 5-10% on adj.
Q3'24 results due 25 October '24e-'26e adj. EBIT revised down 0.
- Weak Q2, -6% on sales and -25% on adj. EBIT vs ABGSCe - FCF generation held back by R&D capitalisation - We cut '24e adj.
- 25% miss on adj EBIT - Lower on sales and weaker gross margin - Estimates likely down 5-8% on adj.
- Q2'24 results due 22 July - 24e-'26e EBIT revised down 1.
Solid earnings beat in Q1 Launch of new system delayed '24e EBIT revised up 8.
43% beat on EBIT Expected launch of new product delayed EBIT '24e expected to be revised up 7-10% Q1 results Net sales came at SEK 147.
Q1'24 results due 7 May '24e-'26e EBIT up 0.8-1.6% due to FX 29-39% below historical NTM P/E and NTM EV/EBIT Q1'24e expectations We forecas...
Underlying earnings better than expected 4.2% organic sales growth in Q4 Near-term uncertainty persists, but long-term potential unchanged ...
Q4'23 results due 6 February Instrument sales to drive growth in Q4e 27-33% below historical NTM P/E and NTM EV/EBITDA Q4'23e expectations ...
4.3% organic sales growth Improved cash flow generation Near-term uncertainty, but long-term potential unchanged Improved sales growth, but...
- Geopolitical situation compromises Boule's performance - 5-part system sales pushed to '25 due to need for improvements - Short-term uncer...
• Macroeconomic situation impacts top-line • Gross profit -11% vs.
Price adjustments and better supply chain lift gross margin EBIT up 15% q-o-q is a good sign Gross margin estimates up by 2pp-1.
Gross margin at 46.2% due to improved market situation New 5-part instrument for veterinary use launch in Q2'23 Conference call at 10:00 CET...
Product mix and price hikes lift gross margin to 44.
Stronger than expected sales but weak EBIT FDA's observations in the US being addressed Conference call today at 10:00 Q4 results Net sales...
Supply chain issues and shortages continue to hit Boule Missed sales by 13% and EBIT by 80% vs.
EBIT missed ABGSCe by 80%, mainly on softer sales Expect cons to cut ‘22e EBIT by 27% There is a conference call at 10:00 CET Q3 results Ne...
Gross margin headwinds shadow ATH sales in Q2 Components and regulator capacity delay new portfolio Estimates cut 28-10%, trading at 12-8x E...
Q2 Sales 3% above but EBIT 66% below Components the issue in Q2, price hikes implemented Cons ‘22e EBIT to come down ~20%, less for ‘23e Q...
23% organic growth for record Q1 sales Margins held back by component situation Trades at 11-8x our EV/EBIT in ‘22e Another record quarte...
Sales in line with better instrument deliveries Strong orderbook but supply and geopolitical uncertainty Presentation at 14.
Component and logistic costs overshadow 34% org. growth In Q2’21, Boule delivered sales that were 2% better than our expectations, as haemat...
